Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial

BACKGROUND: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the cornerstone for prevention ischemic events in patients with acute coronary syndromes (ACS) and undergoing percutaneous coronary intervention. However, the optimal antiplatelet strategy for ACS patients with both high ble...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi, Jing, Quanmin, Wang, Bing, Wang, Xiaozeng, Li, Jing, Qiao, Shubing, Chen, Shaoliang, Angiolillo, Dominick J., Han, Yaling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346838/
https://www.ncbi.nlm.nih.gov/pubmed/32739652
http://dx.doi.org/10.1016/j.ahj.2020.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346838/
https://www.ncbi.nlm.nih.gov/pubmed/32739652
http://dx.doi.org/10.1016/j.ahj.2020.07.005

Ejemplares similares